Bilirubin encephalopathy

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:415286P57
Who is this for?
Show terms as
1Active trials10Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Bilirubin encephalopathy, also known as kernicterus, is a serious brain condition that happens when very high levels of bilirubin — a yellow pigment made when red blood cells break down — build up in a newborn baby's blood and enter the brain. Normally, the liver processes bilirubin and removes it from the body. But in some newborns, bilirubin builds up faster than the liver can handle, causing a condition called jaundice (yellowing of the skin and eyes). If jaundice becomes severe and is not treated quickly, bilirubin can cross into the brain and cause permanent damage. This is called bilirubin encephalopathy or kernicterus. The brain damage from bilirubin encephalopathy can affect movement, hearing, vision, and thinking. Babies may show signs like extreme sleepiness, poor feeding, a high-pitched cry, arching of the back, and seizures. In the long term, survivors may have cerebral palsy, hearing loss, problems with eye movement, and intellectual disabilities. Treatment focuses on lowering bilirubin levels as quickly as possible. The main treatments are phototherapy (special blue lights that break down bilirubin in the skin) and, in severe cases, exchange transfusion (replacing the baby's blood to rapidly reduce bilirubin). When caught and treated early, the outcome can be very good. However, if treatment is delayed, the brain damage can be permanent. Prevention through careful newborn screening and monitoring of bilirubin levels is the most important tool we have.

Also known as:

Key symptoms:

Yellowing of the skin and whites of the eyes (jaundice)Extreme sleepiness or difficulty waking upPoor feeding or weak suckingHigh-pitched or unusual cryingArching of the back and neck backwardSeizuresMuscle stiffness or limpnessHearing lossInvoluntary writhing movements (athetoid cerebral palsy) in survivorsDifficulty controlling eye movements (looking upward is especially hard)Intellectual disability in some survivorsDental enamel problems in baby teeth

Inheritance

Multifactorial

Caused by a mix of several genes and environmental factors

Age of Onset

Neonatal

Begins at or shortly after birth (first 4 weeks)

Orphanet ↗NORD ↗

FDA & Trial Timeline

2 events
Mar 2026Reliability of Transcutaneous Bilirubin Measurement According to the Skin Colour of Newborns

Assistance Publique - Hôpitaux de Paris

TrialNOT YET RECRUITING
Feb 2021Bilirubin Neurotoxicity (BN) and Neurodevelopmental Impairment (NDI) in Extremely Preterm (EP) Infants: Avoidable by Reducing the Usual Intravenous Lipid (UL) Administration

The University of Texas Health Science Center, Houston — PHASE2

TrialACTIVE NOT RECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

No FDA-approved treatments are currently listed for Bilirubin encephalopathy.

1 clinical trialare actively recruiting — trials can provide access to cutting-edge therapies.

View clinical trials →

Clinical Trials

1 recruitingView all trials with filters →
Phase 21 trial
Bilirubin Neurotoxicity (BN) and Neurodevelopmental Impairment (NDI) in Extremely Preterm (EP) Infants: Avoidable by Reducing the Usual Intravenous Lipid (UL) Administration
Phase 2
Active
PI: Lindsay F Holzapfel, MD, MS (The University of Texas Health Science Center, Hou) · Sites: Houston, Texas

Specialists

10 foundView all specialists →
LM
Lindsay F Holzapfel, MD, MS
HOUSTON, TX
Specialist
PI on 1 active trial
JM
Jonathan D Toot, MD
BEAVERCREEK, OH
Specialist
PI on 1 active trial
GL
Global Clinical Leader
Specialist
PI on 44 active trials4 Bilirubin encephalopathy publications
VM
Vinod K Bhutani, MD
PALO ALTO, CA
Specialist
PI on 2 active trials
AM
Angela Okolo, MBBS
Specialist
PI on 1 active trial
AM
Abieyuwa Emokpae, MBBS
HOUSTON, TX
Specialist
PI on 1 active trial
SM
Stephen Oguche, MBBS
Specialist
PI on 1 active trial
ZM
Zubaida Farouk, MBBS
Specialist
PI on 1 active trial
IM
Isa Abdulkadir, MBBS
Specialist
PI on 1 active trial
HM
Hanaa Ab Mohamed
Specialist
PI on 1 active trial

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Bilirubin encephalopathy.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Bilirubin encephalopathyForum →

No community posts yet. Be the first to share your experience with Bilirubin encephalopathy.

Start the conversation →

Latest news about Bilirubin encephalopathy

No recent news articles for Bilirubin encephalopathy.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.What caused my baby's bilirubin to get so high — is there an underlying condition we should test for?,What parts of the brain were affected, and what does that mean for my child's development?,What therapies should we start right away, and how often will my child need them?,Does my child need a hearing test, and if there is hearing loss, what are the options?,Are there any signs I should watch for at home that would mean I need to call you or go to the emergency room?,What early intervention or educational support programs are available for my child?,If we have more children in the future, are they at higher risk for jaundice or bilirubin encephalopathy?

Common questions about Bilirubin encephalopathy

What is Bilirubin encephalopathy?

Bilirubin encephalopathy, also known as kernicterus, is a serious brain condition that happens when very high levels of bilirubin — a yellow pigment made when red blood cells break down — build up in a newborn baby's blood and enter the brain. Normally, the liver processes bilirubin and removes it from the body. But in some newborns, bilirubin builds up faster than the liver can handle, causing a condition called jaundice (yellowing of the skin and eyes). If jaundice becomes severe and is not treated quickly, bilirubin can cross into the brain and cause permanent damage. This is called bilirub

How is Bilirubin encephalopathy inherited?

Bilirubin encephalopathy follows a multifactorial inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Bilirubin encephalopathy typically begin?

Typical onset of Bilirubin encephalopathy is neonatal. Age of onset can vary across affected individuals.

Are there clinical trials for Bilirubin encephalopathy?

Yes — 1 recruiting clinical trial is currently listed for Bilirubin encephalopathy on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Bilirubin encephalopathy?

10 specialists and care centers treating Bilirubin encephalopathy are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.